Altshock-2 REGISTRY

Status Recruiting

Clinical Trial Summary

The study will provide data on profile, management, outcome, and evolution over time of cardiogenic shock patients admitted to the Intensive Coronary Care Units

Clinical Trial Description

Cardiogenic shock (CS) is the most severe form of acute heart failure. Data on epidemiology of CS have been drawn from previously published registries focussing on acute coronary syndrome (ACS) and myocardial infarction (AMI). Indeed, CS occurs in 5-7% of patients presenting with ACS and ACS has been reported as the most prevalent cause of CS, accounting for about 80% of cases. However, recent evidences in a contemporary cohort in North America have shown that more than two-thirds of all cardiogenic shock cases were related to causes other than AMI and that these patients had outcomes at least as poor as patients with AMI-CS. Given the high short-term mortality of these patients and the need for developing dedicated cardiac shock centres and systems of care to time our interventions, it is of utmost importance to achieve a better clinical phenotyping of the heterogeneous causes and presentations of CS patients and carefully perform research outcome. Accordingly, the Altshock-2 registry will represent a unique opportunity to evaluate the full spectrum of CS admitted in Intensive Coronary Care Units and to collect a selected number of variables related to aetiology, clinical presentation, ongoing pharmacological treatments, use of mechanical support devices and outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04295252
Study type	Observational [Patient Registry]
Source	Niguarda Hospital
Contact	nuccia Morici, MD
Phone	+39026444
Email	nuccia.morici@ospedaleniguarda.it
Status	Recruiting
Phase
Start date	July 1, 2020
Completion date	December 31, 2031

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03283995` - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting	`NCT04325035` - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock	Phase 2
Active, not recruiting	`NCT05100836` - SURPASS Impella 5.5 Study
Not yet recruiting	`NCT05106491` - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients	N/A
Completed	`NCT02301819` - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock	N/A
Completed	`NCT01367743` - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock	Phase 4
Recruiting	`NCT05728359` - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting	`NCT05699005` - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO	Phase 1
Not yet recruiting	`NCT06338345` - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients	N/A
Completed	`NCT03436641` - Microcirculation in Cardiogenic Shock
Recruiting	`NCT03313687` - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT04144660` - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed	`NCT04548739` - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting	`NCT04141410` - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting	`NCT05879276` - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.	Phase 3
Enrolling by invitation	`NCT05570864` - Score TO Predict SHOCK - STOP SHOCK
Completed	`NCT02591771` - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock	Phase 2
Terminated	`NCT02279979` - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial	N/A
Completed	`NCT01374867` - CardShock Study and Registry	N/A